EMMA News and Press, Emmaus Life Sciences Incorporation From 08/17/21

Emmaus Life Sciences Announces Bahrain Temporary License of Endari® License Permits Importation and Early Access to Patients Pending Marketing Authorization PR Newswire TORRANCE, Calif. , Aug. 17, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc....

Emmaus Life Sciences Provides SEC Reporting Update 2020 Financial Statements Restated to Reflect Increase in Net Income Attributable to Change in Equity Method Investment in Japanese Affiliate Amended and Restated Form 10-K Includes Complete Restated Financial Statements and...

Emmaus Life Sciences Provides Interim Sales Information Increased Sales Volume in Q2 2021 Reflects Turnaround from Q1 2021 PR Newswire TORRANCE, Calif. , July 22, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell di...

Emmaus Life Sciences Announces Submission of Endari® Marketing Authorization Application in Kuwait PR Newswire TORRANCE, Calif. , July 15, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA) , a commercial-stage biopharmaceutical company and...

Emmaus Life Sciences ([[EMMA]]) has submitted a Marketing Authorization ((MA)) application for Endari to the Swiss Agency for Therapeutic Products (Swissmedic) in Switzerland.Swissmedic's MA review and approval process typically takes 16 to 18 months.Endari will be available to sickle ce...

Emmaus Life Sciences Announces Submission of Marketing Authorization Application to Swissmedic Ideogen, A.G. to Manage Early Access Program PR Newswire TORRANCE, Calif. , June 15, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-...

Emmaus Life Sciences ([[EMMA]] +0.7%) announces that its application for Marketing Authorization ((MA)) for Endari in the Kingdom of Saudi Arabia has been accepted by the Saudi Food and Drug Authority ((SFDA)).The SFDA's MA review and approval process typically takes 12 to 18 months...

Emmaus Life Sciences Announces Submission of Marketing Authorization Application for Endari® to the Saudi Food & Drug Authority Emmaus Life Sciences Announces Submission of Marketing Authorization Application for Endari® to the Saudi Food & Drug Authority P...

Emmaus Life Sciences (EMMA): FY GAAP EPS of $0.02.Revenue of $23.2M (+1.8% Y/Y)Press Release For further details see: Emmaus Life Sciences reports FY results

Emmaus Life Sciences Reports Annual Financial Results for 2020 and Provides Updated Business Review -- Net Revenues Increased Despite COVID-19 Pandemic-Related Challenges -- -- Improved Overall Operating Results and Net Income vs. Net Loss in 2019 -- PR Newswire ...